Medical facility BHealthcare has finalized a deal with three European medical labs for the procurement of several autonomous blood-drawing devices, totaling over 30 units.
In the ever-evolving world of MedTech, BHealthCare, a pioneering European company specialising in autonomous robotic solutions for peripheral vascular access, is making waves with its innovative product, HEIVA.
Since its inception in late 2016, BHealthCare has successfully raised 13.5 million EUR (15M USD) in capital funds and grants, demonstrating the industry's confidence in its vision.
HEIVA, the company's flagship product, is poised to become the first robotic medical technology to autonomously draw blood samples from among thousands of daily patients at selected major European medical laboratory groups. This groundbreaking technology is expected to significantly improve efficiency and safety in blood collection processes.
In a recent article published in "Digital Health & AI Insights" and "Medical Device Manufacturing Insights", the role of data in helping MedTech companies adapt to market changes was discussed. The article did not provide new information about HEIVA but underscored the importance of data-driven innovation in the industry.
BHealthCare has secured supply agreements with three European medical biology laboratories for pre-orders of HEIVA. While the exact number of pre-orders is not disclosed, it is known to be more than 30.
As HEIVA moves towards commercialisation, BHealthCare is currently conducting a fundraising round with the aim of completing HEIVA's pivotal clinical trial and launching its industrial manufacturing process. The company anticipates obtaining CE marking for HEIVA next year, a significant milestone in the regulatory approval process.
HEIVA is currently in the registration process to obtain a CE mark and GCC approval. The article does not provide new information about BHealthCare being one of the first MedTech companies in Europe to offer robotic autonomous blood drawing technology, but it does highlight BHealthCare's position as one of the few companies in the world capable of offering this technology.
The company developed its prototype HEIVA in 2020, which has since undergone pilot clinical evaluation. However, there is currently no information available regarding the current status or potential impact of HEIVA in the European medical market. For the most current and precise details, direct sources such as BHealthCare's official communications, European medical device regulatory announcements, or recent industry reports would be necessary.
As EU cybersecurity measures on MedTech continue to be a topic of discussion, it is clear that BHealthCare is at the forefront of this revolution in laboratory automation, paving the way for a more efficient and safer future in medical diagnostics.
- BHealthCare's innovative product, HEIVA, is expected to revolutionize patient care in the realm of medical-conditions, as it becomes the world's first autonomous robotic technology for blood sample collection in major European medical laboratories.
- The science behind HEIVA is a testament to the power of digital health technology, as it promises to significantly enhance health-and-wellness outcomes through increased efficiency and safety in blood collection processes.
- With the forthcoming commercialization of HEIVA, BHealthCare is set to establish itself as a leading player in the MedTech industry, fostering advancements in technology and contributing to the continuous evolution of medical-conditions diagnosis and management.
